Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2023 18:01 ET | Source: Theralase Technologies Inc.

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
February 21, 2023 07:35 ET | Source: Theralase Technologies Inc.

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
January 25, 2023 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
August 29, 2022 19:45 ET | Source: Theralase Technologies Inc.

Theralase Releases Q222 Interim Financial Statements

TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
June 28, 2022 07:00 ET | Source: Theralase Technologies Inc.

Theralase Expands Intellectual Property Portfolio

TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
June 24, 2022 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Research - One of the Top 10 Most Downloaded Papers

TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
June 21, 2022 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Phase Ib NMIBC Clinical Study Published

TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
May 30, 2022 17:53 ET | Source: Theralase Technologies Inc.

Theralase Releases Q122 Interim Financial Statements

TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
April 29, 2022 21:11 ET | Source: Theralase Technologies Inc.

Theralase Release FY2021 Audited Financial Statements

TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
April 05, 2022 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Provides Update on Phase II Bladder Cancer Clinical Study

TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...

Next Page keyboard_arrow_right